Addex Therapeutics (ADXN) Equity Average: 2024-2025
- Addex Therapeutics' Equity Average fell 100.00% to -$86.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$86.0 million, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $6.1 million for FY2024, which is 91.04% up from last year.
- As of Q2 2025, Addex Therapeutics' Equity Average stood at -$86.0 million, which was up 55.17% from -$191.8 million recorded in Q1 2025.
- Addex Therapeutics' Equity Average's 5-year high stood at $105,605.9 billion during Q1 2024, with a 5-year trough of -$191.8 million in Q1 2025.
- Over the past 2 years, Addex Therapeutics' median Equity Average value was $52,802.8 billion (recorded in 2025), while the average stood at $52,802.8 billion.
- Data for Addex Therapeutics' Equity Average shows a maximum YoY slumped of 100.00% (in 2025) over the last 5 years.
- Addex Therapeutics' Equity Average (Quarterly) stood at $105,605.7 billion in 2024, then plummeted by 100.00% to -$86.0 million in 2025.
- Its Equity Average stands at -$86.0 million for Q2 2025, versus -$191.8 million for Q1 2025 and $105,605.7 billion for Q2 2024.
